PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

Pneumococcal Serotypes

Interested in learning about the serotypes that cause invasive pneumococcal disease in adults?
The serotypes contained in PNEUMOVAX 23 account for the majority of invasive pneumococcal disease (IPD) cases in adults.4
Watch our informative video to learn more about pneumococcal serotypes.

Serotypes Responsible for IPD Cases in Adult Patients

Percentage of IPD cases caused by serotypes contained in PNEUMOVAX 23 — United States 20164

63% of IPD cases in patients ages 65 years and older were due to serotypes contained in PNEUMOVAX 23.

63% of IPD cases in patients ages 65 years and older were due to serotypes contained in PNEUMOVAX 23

75% of IPD cases in patients ages 19 - 64 years were due to serotypes contained in PNEUMOVAX 23.

75% of IPD cases in patients ages 19-64 years were due to serotypes contained in PNEUMOVAX 23

Data derived from the Active Bacterial Core Surveillance Data, unpublished. The figures depict CDC epidemiologic data and do not reflect vaccine efficacy.

ref4

Reference

  1. Centers for Disease Control and Prevention (CDC). Pneumococcal disease: Surveillance and reporting. cdc.gov/pneumococcal/surveillance.html. Updated August 1, 2018. Accessed November 12, 2019.
ref5

Reference

  1. Prevnar 13 [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2019.
ref4-new

Reference

  1. Centers for Disease Control and Prevention (CDC). Pneumococcal disease: Surveillance and reporting. cdc.gov/pneumococcal/surveillance.html. Last Reviewed September 1, 2019. Accessed August 11, 2021.

Indication for PNEUMOVAX 23

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.
Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Do not administer PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) to individuals with a history of a hypersensitivity reaction to any component of the vaccine.

Defer vaccination with PNEUMOVAX 23 in persons with moderate or severe acute illness.

Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

Available human data from clinical trials of PNEUMOVAX 23 in pregnancy have not established the presence or absence of a vaccine-associated risk.

Since elderly individuals may not tolerate medical interventions as well as younger individuals, a higher frequency and/or a greater severity of reactions in some older individuals cannot be ruled out.

Persons who are immunocompromised, including persons receiving immunosuppressive therapy, may have a diminished immune response to PNEUMOVAX 23.

PNEUMOVAX 23 may not be effective in preventing pneumococcal meningitis in patients who have chronic cerebrospinal fluid (CSF) leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures.

The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 for the first time in a clinical trial, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.

For subjects aged 65 years or older in a clinical study, systemic adverse reactions which were determined by the investigator to be vaccine-related were higher following revaccination than following initial vaccination.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the accompanying Prescribing Information. The Patient Information also is available.

PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).

PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

vaxRef

You are about to leave MerckVaccines.com

Vaxelis

Thank you for visiting.


US-PNX-02162 08/21